Advanced Bio Surfaces Receives FDA Clearance To Market For OrthoGlide(R) Medial Knee Implant
Published: Feb 08, 2006
MINNEAPOLIS, Feb. 8 /PRNewswire/ -- Advanced Bio-Surfaces, Inc. (ABS) an orthopedic implant developer and manufacturer, announced today it has received 510(k) clearance to market from the U.S. Food and Drug Administration (FDA) for its OrthoGlide Medial Knee Implant.
The OrthoGlide implant is an innovative design composed of cobalt-chrome alloy intended to replace some of the cartilage functions that have been lost due to osteoarthritis. The implant's unique engineering design provides positional stability without the use of rigid fixation methods. In addition, the specially contoured geometry of the implant provides an open glide path, allowing for the unconstrained motion of the femoral condyle.
"Advanced Bio-Surfaces is excited to expand the surgical treatment options currently available to patients with osteoarthritis. We believe the OrthoGlide Medial Knee Implant may be a better choice for patients facing more invasive treatments, which usually require extensive tissue and bone removal," said Dr. Jeff Felt, Chairman and CEO of Advanced Bio-Surfaces. Dr. Felt continued, "From a technology standpoint this has been an underserved area of orthopedics. The introduction of OrthoGlide represents an excellent opportunity for ABS to capture a significant section of this expanding market."
Dr. David Raab, practicing orthopedic surgeon at Illinois Bone and Joint Institute said, "The OrthoGlide implant was designed and developed using input from multiple orthopedic surgeons." Dr Raab went on to say, "I'm pleased to participate in a post-market clinical study supported by ABS. Data will be collected on OrthoGlide's ability to reduce patient pain and increase knee function through a minimally invasive procedure."
About Advanced Bio-Surfaces, Inc.
ABS is a privately held company dedicated to the development of innovative joint repair products. The company's first product, the OrthoGlide Medial Knee Implant, is intended for treatment of patients with moderate osteoarthritis of the medial compartment. For additional information contact Robert Siegfried at 952.912.5400.Advanced Bio-Surfaces, Inc.
CONTACT: Robert Siegfried, VP, Finance and Administration of AdvancedBio-Surfaces, Inc., +1-952-912-5400
Web site: http://www.advbiosurf.com/